| Literature DB >> 26762507 |
Daniel Felsky1, Philip L De Jager2, Julie A Schneider3, Konstantinos Arfanakis4, Debra A Fleischman5, Zoe Arvanitakis6, William G Honer7, Jennie G Pouget1, Romina Mizrahi1, Bruce G Pollock1, James L Kennedy1, David A Bennett6, Aristotle N Voineskos8.
Abstract
The translocator protein, a microglial-expressed marker of neuroinflammation, has been implicated in Alzheimer's disease, which is characterized by alterations in vascular and inflammatory states. ATSPOvariant, rs6971, determines binding affinity of exogenous radioligandsin vivo; however, the effect of these altered binding characteristics on inflammatory and cerebrovascular biomarkers has not been assessed. In 2345 living subjects (Alzheimer's Disease Neuroimaging Initiative, n = 1330) and postmortem brain samples (Religious Orders Study and Memory and Aging Project, n = 1015), we analyzed effects of rs6971 on white matter hyperintensisites, cerebral infarcts, circulating inflammatory biomarkers, amyloid angiopathy, and microglial activation. We found that rs6971 does not alter translocator protein in a way that impacts cerebrovascular and inflammatory states known to be affected in dementia.Entities:
Keywords: Alzheimer’s; MRI; Microglia; genetics; inflammation; risk factors; white matter disease
Mesh:
Substances:
Year: 2016 PMID: 26762507 PMCID: PMC4821029 DOI: 10.1177/0271678X15626719
Source DB: PubMed Journal: J Cereb Blood Flow Metab ISSN: 0271-678X Impact factor: 6.200